Cargando…
EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
EML4-ALK is an oncogenic fusion protein present in approximately 5% of non–small cell lung cancers (NSCLC). Alternative breakpoints in the gene encoding EML4 result in distinct variants that are linked to markedly different patient outcomes. Patients with EML4-ALK variant 3 (V3) respond poorly to AL...
Autores principales: | Lucken, Kellie, O'Regan, Laura, Choi, Jene, Sampson, Josephina, Pashley, Sarah L., Bayliss, Richard, Khan, Sam, Fry, Andrew M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381094/ https://www.ncbi.nlm.nih.gov/pubmed/35656694 http://dx.doi.org/10.1158/1541-7786.MCR-21-1010 |
Ejemplares similares
-
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022) -
A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
por: Sampson, Josephina, et al.
Publicado: (2022) -
Phase‐separated foci of EML4‐ALK facilitate signalling and depend upon an active kinase conformation
por: Sampson, Josephina, et al.
Publicado: (2021) -
Hsp72 is targeted to the mitotic spindle by Nek6 to promote K-fiber assembly and mitotic progression
por: O’Regan, Laura, et al.
Publicado: (2015) -
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
por: Bayliss, Richard, et al.
Publicado: (2016)